Federal Trade Commission Faces Pharma Antitrust Battle

Federal Trade Commission Faces Pharma Antitrust Battle In the u.s. federal trade commission’s (ftc's) latest campaign against what the agency views as “junk” drug patents listed at the fda, drugmakers have decided not to play ball. The federal trade commission sent letters to companies warning them about over 300 “junk,” or improperly listed, patents for blockbuster drugs like ozempic and saxenda, though drugmakers appear poised to battle the government’s requests.

Federal Trade Commission And 17 States Hit Amazon With Antitrust Lawsuit Once the president elect is sworn in, the higher level of scrutiny from the federal trade commission that ramped up under the biden administration isn’t likely to ease up, according to david balto, an antitrust lawyer and former assistant director of policy and evaluation at the ftc. The pharmaceutical sector is preparing for more antitrust litigation after a pivot by us regulators to lawsuits that prioritize clarifying the law over successfully blocking deals. The federal trade commission plans to hold antitrust hearings later this year, and health care groups haven't been shy about telling regulators this month what they want done with the pharmaceutical industry. Last year, the federal trade commission announced it was ramping up enforcement of illegal rebate schemes for brand name pharmaceuticals that harm generic and biosimilar competition, and began a study looking into the business practices of pharmacy benefit managers.

Tech Industry Cites Economic Downturn In Antitrust Defense The The federal trade commission plans to hold antitrust hearings later this year, and health care groups haven't been shy about telling regulators this month what they want done with the pharmaceutical industry. Last year, the federal trade commission announced it was ramping up enforcement of illegal rebate schemes for brand name pharmaceuticals that harm generic and biosimilar competition, and began a study looking into the business practices of pharmacy benefit managers. Today, the federal trade commission launched a public inquiry into the impact of federal regulations on competition, with the goal of identifying and reducing anticompetitive regulatory barriers. On december 11 of last year, the federal trade commission filed suit to block a partnership between sanofi and maze pharmaceuticals to develop a drug for pompe disease, a partnership that the. After a series of congressional demands and hearings, back and forth with government officials, and a tentative settlement with the justice department over medicaid overcharges, the company says. A flood of biopharma m&a in recent years has prompted the biden administration’s federal trade commission to take another look at how the industry’s mergers affect competition. that could.